In Sepsis, Having the Right Drug Still May Not Be Enough
In conjunction with the initial sales numbers for its sepsis drug, Xigris, manufacturer Eli Lilly cautioned that "the selection of patients with severe sepsis as indicated on the label has been complex for physicians initially." To address the knowledge gap, the National Institutes of Health has awarded a $6 million grant for a study of risk factors for sepsis, the first study of its kind and the biggest single R1 grant ever funded through NIH's National Institute of General Medical Sciences. The Xigris pivotal trial was the only one of 31 Phase III trials of sepsis drugs that didn't fail. "It's not just understanding how the drug works, it's believing in it," says the principal investigator for the NIH study, which should help move the process forward.
Eli Lilly & Co. 's update on
early sales of its sepsis drug, Xigris (drotrecogin alfa, or
activated protein C) serves as a reminder that even with a new drug
finally in hand to treat this often rapidly fatal disease, the
inability to diagnose sepsis early remains a significant clinical
challenge.
Since Xigris's launch in late November, sales have reached $35 million—$14 million of it coming in the first two months...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
